Co-Diagnostics to acquire diagnostic probe technologies from DNA Logix

28 April 2013 (Last Updated April 28th, 2013 18:30)

American provider of personalised medicine and clinical diagnostics, Co-Diagnostics, is set to acquire certain genetic analysis technologies from DNA Logix.

American provider of personalised medicine and clinical diagnostics, Co-Diagnostics, is set to acquire certain genetic analysis technologies from DNA Logix.

Both companies have signed an agreement towards this effect, which is believed will help Co-Diagnostics make further inroads into the fast-growing molecular diagnostics market.

Co-Diagnostics is purchasing three patent applications and several trade secrets that the company claims will enable high-performance DNA testing with advanced sensitivity and specificity.

"Co-Diagnostics is purchasing three patent applications and several trade secrets that the company claims will enable high-performance DNA testing with advanced sensitivity and specificity."

The technology was part of several inventions made by DNA Logix founder Dr Brent Satterfield prior setting up the company.

Co-Diagnostics president Dwight Egan said that DNA Logix's technology has the recognition of major diagnostic manufacturers and international pharmaceutical partners.

"With this technology, we believe our highly efficient assay development capability, combined with superior results and efficient costs, will result in our unique approach to DNA testing being sought after by developers of powerful diagnostics in a wide range of markets," said Egan.

Co-Diagnostics said that the notable technology among Satterfield's inventions is the Tentacle probe, which is a new class of DNA diagnostic probe.

Believed to be up to 200 times faster compared to others, the Tentacle probe is up to 10,000 times more specific in high concentrations of contaminant, and up to 13 times more robust in extreme temperature conditions.